A popular trend in current dose-finding studies moves away from traditional rule-based study designs (e.g. 3+3) and instead uses model-based designs to make dosing decisions during a trial. In this video from Cytel and Sanofi/Genzyme's single day forum on early phase oncology studies, Ling Wang of Takeda Pharmaceuticals gives a talk on single-agent and combination dose-finding designs.
Related Items of Interest
[1] Bayesian Dose Escalation Designs for Late Onset Toxicity
[2] 2 Talks on Early Phase Go/No-GO Decision Making